NEW HAVEN, Conn., March 19, 2018 /PRNewswire/ -- Arvinas LLC, a private biotechnology company creating a new class of drugsbased on protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer of Arvinas, will present a company overview at the 17th Annual Needham Healthcare Conference on
About ArvinasArvinas is a pharmaceutical company focused on developing new small molecules ? known as PROTACs (PROteolysis TArgeting Chimeras) ? aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting "undruggable" as well as "druggable" elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets. For more information, visit www.arvinas.com.
View original content:http://www.prnewswire.com/news-releases/arvinas-to-present-at-the-17th-annual-needham-healthcare-conference-300615703.html
Subscribe to our Free Newsletters!
Pneumonitis usually refers to inflammation of lung tissue due to various non-infective causes such ...
Fremanezumab-vfrm is used as a preventive treatment for a migraine headache in adult patients. It ...
DOOR syndrome is a rare genetic disorder marked by deafness, short or absent fingernails, abnormal ...View All